Earnings Insights · PFE · Q3 FY2026
Pfizer Q3 2026 Earnings: Core Products Offset COVID Declines as Guidance Rises
By AlgovestIQ ResearchPublished
Read Pfizer’s results announcement (Form 8-K, filed Nov 3, 2026)
Key earnings findings
Pfizer (PFE) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Pfizer reported Q3 FY2026 revenue of $16.58B against the $15.85B analyst estimate, a 4.6% beat, and EPS of $0.87 against the $0.73 analyst estimate, a 18.4% beat.
- The company raised its full-year revenue outlook by $1.5B at the midpoint and increased adjusted EPS guidance despite greater R&D spending.
- PFE closed at $30.00 on Nov 3, 2026, down 2.2% from $30.67 on Nov 2, 2026, the last close before the results were released.
Sources: Pfizer results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Pfizer beat earnings expectations?
- EPS has beaten the estimate in all 8 of the most recent reported quarters on record.
- Revenue surprise across the last 8 reported quarters has ranged from -1.5% to 8.1%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Pfizer reported third-quarter revenue of $16.6B, essentially flat from a year earlier, while reported diluted EPS fell 9% to $0.56 and adjusted diluted EPS held at $0.87. The headline result masked a clearer improvement in the underlying commercial portfolio: revenue excluding Comirnaty and Paxlovid grew 7% operationally, led by Eliquis, Padcev, Vyndaqel, Nurtec and Lorbrena.
The company raised its full-year revenue outlook by $1.5B at the midpoint and increased adjusted EPS guidance despite greater R&D spending. The central issue for investors remains whether growth from newer and acquired medicines can offset COVID-product declines and a larger patent-expiry cycle beginning in 2027.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Total revenue | $16.6B | Flat year over year |
| Operational revenue growth, excluding Comirnaty and Paxlovid | 7% | — |
| Launched and acquired products revenue growth | 32% operationally | — |
| Reported net income | $3.2B | Down 8% |
| Reported diluted EPS | $0.56 | Down 9% |
| Adjusted diluted EPS | $0.87 | Flat |
| Biopharma revenue | $16.3B | Flat |
| Pfizer CentreOne revenue | $300M | Down 13% |
| Primary Care revenue | $7.0B | Down 9% |
| Oncology revenue | $4.3B | Up 10% |
| Specialty Care revenue | $3.3B | Up 7% |
| Hospital and Biosimilars revenue | $1.6B | Up 2% |
| Adjusted gross margin | 77% | Up from 76.1% |
| Adjusted operating margin | 36% | — |
| Operating cash flow, first nine months | $8.8B | — |
| Leverage | 2.6x | Below 2.7x 2026 target |
The Bigger Story
Pfizer’s quarter reinforced the split within its business. The legacy COVID franchise remains a material drag, with Paxlovid revenue down 63% operationally and Comirnaty down 29%. But growth brands, including medicines acquired through Seagen and Biohaven, are increasingly carrying the portfolio.
Launched and acquired products generated $3.8B of quarterly revenue and grew 32% operationally. Acquired products alone grew 37% operationally, according to management, with the former Seagen portfolio up 39% in the U.S. The acquired portfolio is therefore becoming a more important offset to Pfizer’s loss-of-exclusivity exposure, particularly in oncology.
That offset is not yet sufficient to produce total-company growth. Revenue was flat even as several major brands delivered double-digit gains, underscoring the size of the COVID decline and the pressure in vaccines and older products. Pfizer’s investment case still depends on execution through the 2027-2029 patent-expiry period, followed by a greater contribution from its pipeline and newer commercial assets.
Revenue and Operating Performance
Growth brands led by Eliquis and oncology
Eliquis revenue rose 25% operationally to $2.5B. Pfizer attributed the increase to higher U.S. net price, reflecting lower rebates and favorable channel mix, as well as higher global demand. International performance was softer, with generic competition and price erosion largely offsetting demand growth outside the U.S.
Oncology revenue increased 10% operationally to $4.3B. Padcev was the largest contributor, rising 55% operationally to $720M, supported by market-share gains in first-line locally advanced or metastatic urothelial cancer and uptake in a cisplatin-ineligible muscle-invasive bladder-cancer indication.
Other notable oncology gains included:
- Lorbrena: Revenue of $387M, up 43% operationally, driven by patient-share gains in first-line ALK-positive metastatic non-small cell lung cancer.
- Orgovyx: Revenue of $153M, up 37%.
- Tukysa: Revenue of $142M, up 30% operationally.
- Braftovi/Mektovi: Revenue of $244M, up 21%.
Specialty Care revenue grew 7% operationally to $3.3B. The Vyndaqel family generated $1.8B, increasing 12% operationally, as diagnosis and treatment adoption expanded in the U.S. and internationally. Nurtec ODT/Vydura revenue grew 33% to $547M, with U.S. demand and international launches driving the gain.
Management said Nurtec is leading the U.S. oral CGRP migraine category and cited expanding access in markets including the U.K., Italy and Japan. However, the franchise remains in a competitive therapeutic category, making continued growth and international execution important.
COVID, Prevnar and older products remained drags
Paxlovid revenue fell 63% operationally to $449M, reflecting lower COVID-19 infection rates. Comirnaty revenue declined 29% operationally to $808M, affected by lower U.S. utilization after narrower vaccine recommendations, a smaller favorable adjustment to U.S. return reserves, and lower international contractual deliveries.
Pfizer expects approximately $4B of full-year revenue from COVID products, with most Comirnaty revenue expected in the fourth quarter during the vaccination season. That expectation leaves the company exposed to infection rates, treatment demand and vaccine uptake.
Prevnar family revenue declined 10% operationally to $1.6B. Lower adult and pediatric vaccination rates, adult-market share erosion in the U.S., and softer pediatric demand in certain international markets were the main factors. The decline matters because Prevnar remains one of Pfizer’s largest franchises and highlights the need for its next-generation pneumococcal vaccine programs to succeed.
Primary Care revenue fell 9% operationally to $7.0B, largely because the COVID and Prevnar declines outweighed gains from Eliquis and Nurtec.
Profitability and Margins
Reported diluted EPS declined to $0.56 from $0.62, while reported net income fell 8% to $3.2B. Adjusted diluted EPS was unchanged at $0.87, and adjusted income increased 1% to $5.0B.
The divergence reflects the impact of items excluded from Pfizer’s adjusted metrics, including intangible amortization, restructuring costs, acquisition-related items and other significant charges. Reported R&D expense rose 18% operationally to $3.0B, driven by higher spending on oncology and obesity candidates as well as compensation costs.
Pfizer recorded a $650M acquired in-process R&D charge tied to its Innovent Biologics in-licensing and collaboration agreement. Management said the charge reduced adjusted EPS by approximately $0.10. The comparison was favorable year over year because the prior-year quarter included a larger $1.35B acquired IPR&D charge related to 3SBio.
Adjusted gross margin expanded to 77%, aided by favorable product mix and cost management. Reported cost of sales as a percentage of revenue declined 0.8 percentage points to 24.3%, also benefiting from product mix and foreign exchange.
Cost discipline remains a core part of Pfizer’s plan to navigate upcoming patent expirations. Management said it expects to deliver nearly all of the previously announced $7.2B in net savings from ongoing programs by the end of 2026. It has also initiated a further program targeting $2.5B in net savings from 2027 through 2029.
Still, restructuring costs remain substantial. Pfizer recorded $791M of restructuring and acquisition-related costs during the quarter, including $742M related primarily to employee termination costs under its enterprise-wide cost realignment program.
Demand, Customers and Pricing
The quarter’s underlying growth was driven more by demand and product uptake than by broad gross-to-net benefits, according to management. The principal pricing exception was Eliquis, where U.S. revenue benefited from pricing dynamics including lower rebates and favorable channel mix.
Management said it expects several pricing and access variables to affect 2027, including Inflation Reduction Act negotiations involving two Pfizer products, changes to 340B reimbursement mechanics, and implications from the company’s government agreements related to most-favored-nation pricing. These factors will be reflected in Pfizer’s 2027 guidance, expected in mid-December.
The company expects international Eliquis revenue to face continued generic competition and price erosion. Its broader portfolio also faces approximately $1.1B of anticipated unfavorable revenue impact in 2026 from generic and biosimilar competition.
What is Pfizer’s guidance for full-year 2026?
Pfizer raised full-year 2026 revenue guidance to $62.0B to $64.0B, from $60.5B to $62.5B previously. The new range raises the midpoint by $1.5B.
The company also raised and narrowed adjusted diluted EPS guidance to $2.95 to $3.05, from $2.80 to $3.00. This outlook includes the approximately $0.10-per-share unfavorable impact from the Innovent acquired IPR&D charge.
| Guidance Metric | Full-Year 2026 Guidance |
|---|---|
| Revenue | $62.0B to $64.0B |
| Adjusted SI&A expense | $12.5B to $13.5B |
| Adjusted R&D expense | $10.8B to $11.8B |
| Adjusted tax rate | Approximately 15.0% |
| Adjusted diluted EPS | $2.95 to $3.05 |
Management reaffirmed its expectation for approximately $4B in combined Comirnaty and Paxlovid revenue in 2026. It also expects adjusted gross margin in the mid-70% range for the full year.
Beyond 2026, management said it sees a path to risk-adjusted high-single-digit revenue CAGR from year-end 2028 through year-end 2033. That is an aspiration rather than formal financial guidance and depends on continued growth from newer products, successful pipeline development and management of loss-of-exclusivity headwinds.
Pipeline and Strategic Developments
Pfizer’s late-stage pipeline is increasingly important because management expects major loss-of-exclusivity pressures to intensify from 2027. Recent progress included eight pivotal study starts, one pivotal readout and two regulatory decisions.
Key developments include:
- Elrexfio: A Phase 3 study met its progression-free survival endpoint in relapsed or refractory multiple myeloma. Management believes the results support efforts to move the therapy into earlier treatment lines, though regulatory success and adoption remain necessary.
- Tilrekimig: Phase 2 atopic dermatitis data met the primary endpoint. Pfizer has begun Phase 3 programs in atopic dermatitis and severe asthma, while a Phase 2b/3 program in COPD is ongoing.
- Berobenatide and obesity portfolio: Pfizer plans 10 active and planned Phase 3 trials in 2026. Management is targeting a first potential berobenatide approval in 2028. The amylin combination Phase 2b study is fully enrolled, with efficacy results expected in the second half of 2027.
- Mevrometostat: The MEVPRO-1 prostate-cancer study is now expected to read out in the first quarter of 2027, while MEVPRO-2 is expected in the fourth quarter of 2027.
- Next-generation pneumococcal vaccines: Pfizer’s 25-valent pediatric candidate produced supportive Phase 2 results, and its Phase 3 program is underway. The company expects to begin a Phase 1 adult study for its 35-valent candidate this year.
The pipeline also carries execution risk. During the first nine months of 2026, Pfizer recorded $4.3B in intangible-asset impairments related to unfavorable Phase 3 results for sigvotatug vedotin and $525M related to Oxbryta rights after determining there was no viable path to return the product to the U.S. market.
Balance Sheet, Cash Flow and Capital
Pfizer generated $8.8B in operating cash flow during the first nine months of 2026. Management said leverage ended the quarter at 2.6x, slightly below its 2026 target of 2.7x.
The company deployed $8.3B to internal R&D during the first nine months and approximately $850M on business-development transactions, primarily the Innovent agreement. It also returned $7.3B to shareholders through dividends, equal to $1.29 per share.
Pfizer does not expect share repurchases in 2026, despite having $3.3B remaining under its authorization. Management said buybacks could again become part of capital allocation after the loss-of-exclusivity transition, but near-term priorities remain investment, dividend support and balance-sheet flexibility. Following the Innovent deal, management put its current business-development capacity at approximately $6B.
What Investors Should Watch
1. Conversion of growth brands into total-company growth
Eliquis, Padcev, Nurtec, Vyndaqel and Lorbrena are offsetting COVID declines, but total revenue was still flat. Investors should watch whether growth from the launched and acquired portfolio can overcome the continuing decline in Paxlovid, Comirnaty, Prevnar and older franchises.
2. The 2027 loss-of-exclusivity outlook
Pfizer expects material pressure from patent expirations, including Ibrance and Xtandi in the U.S. and Eliquis internationally. Its December 2027 guidance will provide the clearest near-term view of the revenue and margin transition.
3. Pricing and reimbursement changes
IRA negotiations, 340B policy changes and government pricing agreements could affect U.S. net pricing. Eliquis was a meaningful contributor to third-quarter growth, so its pricing trajectory warrants close attention.
4. Pipeline readouts and regulatory execution
Mevrometostat, Elrexfio, tilrekimig, the obesity program and next-generation vaccines are central to Pfizer’s post-2028 growth case. Positive data alone will not be enough; approvals, differentiation and commercial uptake will determine their value.
5. Cost savings versus reinvestment needs
Pfizer’s savings programs support margins, but R&D spending rose 18% as the company advanced late-stage oncology and obesity studies. Investors should monitor whether incremental savings can protect earnings while Pfizer funds the pipeline required to replace maturing products.
AlgovestIQ Takeaway
Pfizer delivered a better underlying commercial quarter than its flat revenue headline suggests. Excluding Comirnaty and Paxlovid, operational revenue growth reached 7%, and the launched and acquired portfolio grew 32%. Padcev, Nurtec, Lorbrena, Vyndaqel and Eliquis demonstrate that Pfizer has several sizable growth drivers rather than reliance on a single new franchise.
The raised 2026 outlook is also constructive. Pfizer increased both revenue and adjusted EPS guidance while absorbing the Innovent charge and continuing to invest more aggressively in R&D. Gross-margin improvement and the cost-reduction program provide some evidence that management can fund pipeline investment without abandoning operating discipline.
However, the company remains in transition. COVID revenues are still declining sharply, Prevnar is under pressure, and the larger loss-of-exclusivity challenge begins in 2027. Management’s long-term growth ambition depends on commercial execution from acquired assets and successful development of an unusually broad set of pipeline programs.
The central investment question is whether Pfizer can convert its growing newer-product base and late-stage pipeline into enough revenue to offset patent losses while preserving margins and dividend capacity. Evidence supporting that case would include sustained double-digit growth from oncology and migraine products, resilient Eliquis economics, credible 2027 guidance, and positive pivotal data from the obesity, oncology and vaccine portfolios. Weakening demand in major franchises, adverse pricing effects, further pipeline setbacks or slower-than-expected uptake of newer medicines would challenge that path.
How did PFE stock react?
PFE closed at $30.00 on Nov 3, 2026, down 2.2% from $30.67 on Nov 2, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Nov 2, 2026 (before release) | $30.67 | — |
| Nov 3, 2026 | $30.00 | -2.2% |
| Nov 4, 2026 | $30.79 | +0.4% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- AMGNAmgen Q3 2026 Earnings: Growth Portfolio Offsets Biosimilar Erosion as IMDELLTRA Opportunity ExpandsNov 3, 2026
- NVONovo Q3 2026 Earnings: GLP-1 Volumes Recover as Guidance Rises AgainNov 4, 2026
- ABBVAbbVie Q3 2026 Earnings: Skyrizi and Rinvoq Drive Another Guidance IncreaseOct 30, 2026
- LLYEli Lilly Q3 2026 Earnings: Guidance Rises as Mounjaro and Zepbound Drive $24.4B QuarterOct 29, 2026
- MRKMerck Q3 2026 Earnings: Sales Growth Holds, but Purchase Timing and Higher Investment Pressure EPSOct 29, 2026
Compare PFE with
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Pfizer Q3 FY2026 earnings call transcript, as of Nov 3, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Pfizer Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 3, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 3, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.